All In Biotech

Drug Trial Radar · NCT06966635

Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets

Last checked: Nov 20, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

312

Planned (sponsor's estimate)

Start

Apr 10, 2024

Primary completion

Dec 31, 2025

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Huashan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate whether alkalization has the effect of lowering uric acid and reducing gout flare and determine whether alkalization has a role in the prevention and treatment of urinary calculi in gout, the research participants were divided into the control group, the potassium citrate group and the sodium bicarbonate group. 2 alkalization groups took potassium citrate three times a day 2.16g each time, or sodium bicarbonate three times a day, 1.0g each time, on the basis of the standard uric acid-lowering treatment plan. The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable.

Conditions

  • Hyperuricemia or Gout
  • Nephrolithiasis

Interventions

  • Sodium Bicarbonate Oral CapsuleDrug

    On the basis of the standard uric acid-lowering treatment plan, sodium bicarbonate should be taken three times a day, 1.0g each time

  • Potassium Citrate TabletsDrug

    On the basis of the standard uric acid-lowering treatment plan, potassium citrate was taken three times a day, 2.16g each time

  • uric-acid-lowering drugDrug

    The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable. The treatment plan for lowering uric acid remained unchanged for 4 weeks after enrollment in the clinical study until the endpoint.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. serum uric acidTime frame: From enrollment to the end of treatment at 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan hospital, Fudan university

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.